רÀûÃû³Æ£ºÒ»´ÎÐԵ绯ѧоƬµÄÖÆ×÷·½·¨
¼¼ÊõÁìÓò£º
±¾ÊµÓÃÐÂÐÍÒ»´ÎÐԵ绯ѧоƬ£¬ÊôÓÚµÚ¶þ´úÉúÎïоƬ£¬¿ÉÒÔÓÃÐÂÐÍÄÉÃײÄÁϼ°ÉúÎïѧ·Ö×Ó½øÐÐÐÞÊΣ¬²¢¿ÉÓë¶àͨµÀºãµçλÒÇÏàÁ¬½ÓºÍ²âÊÔ¡£ÔÚÿÕŵ绯ѧоƬÉ϶¼º¬ÓÐ16 ¸ö¶ÀÁ¢·ÖÎö΢¿×£¬µç»¯Ñ§Ð¾Æ¬¼¯³É¶È¸ß£¬Ò×ÓÚÅúÁ¿Éú²ú£¬ÐÔÖÊÎȶ¨£¬·Ç³£ÊʺÏÔÚÒ½Ôº¼ìÑé¿ÆÓ¦Óá£ÀûÓôËоƬ¿ÉÒÔÖ±½Ó¶ÔÁÙ´²Äò·³£¼û¸ÐȾ²¡Ô¾ú½øÐмø¶¨¼°Ò©Ãô·ÖÎö£¬¶ø²»ÓöԲ¡Ô¾ú½øÐÐÅàÑø»ò»ùÒòÀ©Ôö£¬ÁÙ´²±ê±¾¼ì²âÁ¿Ð¡(3-50 ¦Ì L)£¬×¼È·¶È¸ß£¬ÌØÒìÐÔÇ¿£¬Õï¶Ïʱ¼ä¶Ì¡£
±³¾°¼¼Êõ£º
Äò·¸ÐȾ²¡Ô¾ú¼ì²â½ð±ê׼ͨ¹ý³£¹æÏ¸¾úÅàÑø¼°Ò©ÃôʵÑé½øÐмì²â£¬Æä²»×ãÖ®´¦ÊÇÖÁÉÙÐèÒª2-3ÌìµÄʱ¼ä²ÅÄÜ´ÓÁÙ´²±ê±¾ÖзÖÀëÅàÑø³öÖ²¡¾úÖêÒÔ¼°Íê³ÉÏà¹ØÒ©Ãô²âÊÔ£¬¶øÇÒһЩÉú³¤»ºÂýºÍ²»Ò×ÅàÑøµÄÄò·²¡Ô¾úÊÇÎÞ·¨Í¨¹ý³£¹æÒ©ÃôÊÔÑé·½·¨½øÐмì²â£¬ ÔÚȱ·¦¿ìËÙ΢ÉúÎïÕï¶ÏµÄÇé¿öÏ£¬ÁÙ´²Ò½ÉúºÜ¿ÉÄÜ¾Í»áÆ¾¾ÑéÖ÷ÒåÀ´½øÐп¹ÉúËØÓÃÒ©£¬ÑÓÎóÁ˶Բ¡ÈËÖÎÁƵÄ×î¼Ñʱ»ú¡£ÒÔ¾ÛºÏøÁ´Ê½·´Ó¦(PCR)Ϊ»ù´¡µÄʵʱӫ¹â¶¨Á¿PCR¼¼Êõ¿ÉÒÔ´Ó·Ö×ÓÉúÎïѧˮƽ¼ì²âϸ¾ú[1_2]¡£¸Ã·½·¨¿ÉÒÔÖ±½Ó´ÓÁÙ´²±ê±¾ÈëÊÖ£¬¶øÎÞÐë¾úÖêµÄÅàÑø£¬Õû¸öʵÑé¹ý³ÌÐèÒª4-6 Сʱ¡£µ«ÊÇ£¬³£¹æ·Ö×ÓÉúÎïѧ·½·¨¶Ôÿһ¸ö²âÊԵĿ¹¾úÒ©Î¾ùÐèÒªÉè¼ÆÏàÓ¦µÄ·Ö×Ó¼ì²â·½·¨£¬Ò»´ÎÖ»ÄÜ·ÖÎöÒ»ÖÖϸ¾ú¦Ø¡£»ùÒòоƬ¼¼Êõ×ÔÎÊÊÀÒÔÀ´[4]£¬ÒÔÆä»ùÓÚºËËáÔÓ½»µÄ¼ì²â¸ß¶ÈÌØÒìÐÔ£¬¼ì²âʱµÄ¸ßͨÁ¿ÒÔ¼°Æ½ÐзÖÎöµÄÌØµã[5_8]£¬1998Äê±»ÃÀ¹ú¿ÆÑ§´Ù½ø»áÆÀΪµ±ÄêÊ®´ó¿Æ¼¼½øÕ¹Ö®Ò» [9]£¬²¢ÎªÁÙ´²Ï¸¾ú¼ì²âÌṩÁ˸ßЧ¡¢¸ß¶ÈÌØÒìµÄÕï¶Ï¼¼Êõ£¬Ò²ÎªÒ½Ñ§Õï¶Ï¼°ÖÎÁƼ¼Êõ½ø²½×ö³ö½Ü³öµÄ¹±Ï×£¬½â¾ö´«Í³»ùÒòÕï¶Ï¼¼ÊõËù²»Äܽâ¾öµÄϵÁÐÄÑÌâ[1¡ã_11]¡£µ«ÊÇ´«Í³µÄ»ùÒòоƬ¼¼Êõ£¬ÎÞÂÛÊÇ΢ÕóÁУ¬»¹ÊÇÔλºÏ³ÉµÄ¹ÑºËÜÕËá»ùÒòоƬ£¬¾ùʹÓÃÓ«¹â±ê¼Ç̽Õë¼¼Êõ[12_13]£¬Ó¦ÓÃʱÐèÒª°º¹óµÄ¼¤¹âɨÃèÉ豸[14]£¬´ËÍ⣬´«Í³¼¼Êõ²»ÄÜÍêÈ«Ïû³ýϸ¾ú¼ì²âʱµÄÒõÐÔÐźţ¬ÒõÑôÐÔÐÅÔë±È¶Ô±ÈµÍ£¬´æÔÚÈËΪÅÐ¶ÏÆäÒõÑôÐÔ½á¹û.ÕâЩÒòËØÑÏÖØÖÆÔ¼ÁË»ùÒòоƬ¼¼ÊõÔÚÁÙ´²Ï¸¾ú¼ì²â¼°Ò©Ãô·ÖÎöÖеĹ㷺ӦÓᣲο¼ÎÄÏ×l.ffolff BJ, Thacker WL, Schwartz SB, Winchell JM. Detection of macroIide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Ch,2008,52(10) :3542-3549.2. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, Boilloit F, Peeters M. Evalua-tion of different RNA extraction methods and storage conditions of dried plasma or blood spots for human immunodeficiency virus type 1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol,2009,47(4) :1107-1118.3. Hindiyeh M, Ram D, Mandelboim M, TMeningher T, Hirsh S, Robinov J, LevyV, Orzitzer S, Azar R, Grossman ¦¦, Mendelson ¦¥. Rapid detection ofinfluenza A pandemic (HlNl)2009virus neuraminidase resistance mutation H275Y by real-time RT-PCR. JClin Microbiol,2010,48(5) :1884-1887.4.Fodor SP, Read JL, Pirrung MC, Stryer L, Lu AT, Solas D.Light-directed, spatially addressable parallel chemical synthesis. Science 1991,251:767-7735.Pellois JP, Zhou X, Srivannavit 0, Zhou T, Gulari E, Gao X.Individually addressable parallel peptide synthesis on microchips. Nat Biotechnol 2002,20: 922-92266. Schena M, Shalon D, Heller R, Chai A, Brown PO, Davis Rff. Parallelhuman genome analysis :microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci USA 1996,93 :10614-106197. Lockhar t DJ, Winzeler EA.Genomics, gene expression and DNA arrays. Nature, 2000,405 :827-8368. Xiao Y, Segal MR, Yang YH, Yeh RF. A multi-array multi-SNP genotyping algorithm for Affymetrix SNP microarrays. Bioinformatics, 2007, 23 :1459-14679.Breakthrough of the year. The runners-up. Science, 1998, 282 :2157-216110. Gerhold DL, Jensen RV, Gul Ians SR. Bet ter therapeutics through microarrays. Nat Genet,2002, 32 :547-55111.Ragoussis J, Elvidge G.Affymetrix GeneChip system:moving from research to the clinic.Expert Rev Mol Diagn, 2006,6 :145-15212. Shomaker TS, Ward K. Microarray technology inbiomedical research. Hawaii Med£¬2006£¬65 :253-25613. Duyk GM. Sharper tools and simpler methods. Nat Genet,2002,32 Suppl 465-46814. Schena M, Shalon D, Davis Rff, Brown P0. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science,1995,270 467-470
·¢Ã÷ÄÚÈÝΪÁ˿˷þĿǰÁÙ´²Äò·²¡Ô¾ú¼ì²â¼°Ò©Ãô·ÖÎöºÄʱ³¤£¬²Ù×÷·±Ëö£¬¼ì²âÁ¿µÍ¼°¼ì²â³É±¾¸ßµÄÎÊÌ⣬±¾ÊµÓÃÐÂÐÍÌṩÁËÒ»ÖÖÒ»´ÎÐԵ绯ѧоƬ¡£±¾ÊµÓÃÐÂÐͽâ¾öÒÔÉÏÎÊÌâËù²ÉÓõļ¼Êõ·½°¸ÊÇ(1)ÔÚ²£Á§°åÉÏÒ»´ÎÐÔ¼Ó¹¤ÉÏ16¸ö΢·´Ó¦¿×£¬Ã¿¸ö΢¿×°üÀ¨ÓɽðÄÉÃ×µ¼µç²ÄÁϹ¹³ÉµÄÈý¸ö΢µç¼«¹¤×÷µç¼«£¬¸¨Öúµç¼«£¬²Î±Èµç¼«¡£(2)ÔÚÿ¸ö¹¤×÷µç¼«±íÃæ¹¹½¨Í黯ÛÏ»ù×Ô×é×°·Ö×Ӳ㣬ȻºóÔÙÓÃNHSºÍEDC¶Ô×Ô×é×°²ã¹¦ÄÜ»¯£¬²¢½«ÉúÎïËØºÍÇ׺ÍËØÐÞÊε½¹¤×÷µç¼«ÉÏ¡£×¢¹¤×÷µç¼«ÉÏ»¹¿ÉÒÔÐÞÊÎNH2¡¢C00H¡¢ÉúÎïËØ¡¢Ç׺ÍËØ¡¢À±¸ù¹ýÑõ»¯Îïø¡¢¿¹Ìå¡£(3)ÀûÓÃÉúÎïÐÅϢѧ¼¼Êõ£¬ÖÆ×÷ºÍÄò·²¡Ô¾ú16SrRNAÌØÒìÐÔ±£ÊØÐòÁÐÏ໥²¹µÄÒ»¿¹±ê¼ÇµÄ¼ì²â̽ÕëÓëÇ׺ÍËØ»¯µÄ²¶»ñ̽Õ룬²¢½«Ç׺ͻ¯µÄ²¶»ñ̽ÕëÐÞÊε½¹¤×÷µç¼«±í
4Ãæ¡£×¢16S rRNAΪËùÓÐϸ¾úËù¹²ÓУ¬Æä±àÂë»ùÒò¼æ±£ÊØÐԺͱäÒìÐÔÓÚÒ»Éí£¬ËØÓÐϸ¾úµÄ¡°·Ö×Ó»¯Ê¯¡±Ö®³Æ¡£16SrRNA»ùÒòµÄ±£ÊØÐÔÓÖÊÇÏà¶ÔµÄ£¬ÔÚ±£ÊØÇøÖ®¼ä´æÔÚ×Å9¸ö»ò10¸ö±äÒìÇø(VI V10)£¬²»Í¬¿Æ¡¢Êô¡¢Öּ䶼Óв»Í¬³Ì¶ÈµÄ²îÒ죬ÀûÓÃVl-VlO¼äµÄ±äÒì½øÐÐÖÖÊôÌØÒìÐÔ̽ÕëÉè¼Æ¡£Ì½ÕëΪ¹ÑºËÜÕËá̽Õë»òëĺËËá(PNA)̽Õë¡£(4)ÁÙ´²±ê±¾´¦Àí½«ÄòÒºÀëÐÄÎå·ÖÖÓ£¬È»ºóÔÙ¼ÓÈëNaOH¡¢TritonX-100¡¢EDTA¡¢Èܽâ½ÍËØ¡¢TRIS-HCL£¬ÔÚÊÒÎÂÏ·õÓý5·ÖÖÓ£¬½«¼ì²â̽Õë»ìºÏÒº¼ÓÈ뵽ϸ¾úÁѽâÒºÖзõÓýºÍϸ¾ú°Ð16SrRNAÌØÒìÐÔ±£ÊØÐòÁгä·ÖÔÓ½»£¬½«4 ¦Ì L»ìºÏÒº¼ÓÈ뵽оƬ΢¿×ÖУ¬µÈ³ä·Ö·õÓý£¬ÔÙ¼ÓÈë HRP ºÍ TMB-H2O2¡£(5)оƬ¼ì²âÀûÓÃÌØÖÆµÄµç»¯Ñ§Ð¾Æ¬¶ÁÊýÆ÷ºÍ¶àͨµÀºãµçλÒÇÏàÁ¬½Ó£¬½«Ð¾Æ¬Éϵķ´Ó¦Ðźţ¬ÒԿɶÁµÄµçÐźÅÊä³ö£¬´Ó¶øÈ·¶¨Ï¸¾úÖÖÀ༰½øÒ»²½Ò©Ãô·ÖÎö¡£¸ÃÒ»´ÎÐԵ绯ѧоƬ²»½öÄܶÔÁÙ´²Äò·³£¼û²¡Ô¾ú½øÐпìËÙ¼ì²â(45·ÖÖÓ)ºÍ¿ìËÙÒ©Ãô·ÖÎö(3. 5Сʱ)£¬¶øÇÒºÍĿǰ³£ÓöàͨµÀºãµçλÒÇ¿ÉÒÔÏà½áºÏ£¬´ó´ó½µµÍÁ˼ì²â³É±¾¡£
ͼ1ÊDZ¾ÐÂÐ͵绯ѧоƬÁ¢Ìåͼ¡£Í¼2ÊDZ¾µç»¯Ñ§Ð¾Æ¬µÄÏàÓ¦¶ÁÊýÆ÷Á¢Ìå¼òͼ¡£Í¼3ÊǶÁÊýÆ÷¶Ôµç»¯Ñ§Ð¾Æ¬½øÐжÁÊý¼òͼ¡£ÔÚͼÖТŵ绯ѧоƬ²£Á§µ×°å£¬(2)¸¨Öúµç¼«£¬(3)¹¤×÷µç¼«£¬¢È²Î±Èµç¼«£¬(5) ·´Ó¦Î¢¿×£¬(6)¶ÁÊýÆ÷оƬ²Û£¬(7)·´Ó¦ÐźÅÊä³öµ¼Ïߣ¬¢Ç¶ÁÊýÆ÷Æ½ÃæÍ¼£¬(9)µç»¯Ñ§Ð¾Æ¬Æ½ÃæÍ¼.
¾ßÌåʵʩ·½°¸ÓÉͼ1¿É¼û£¬±¾µç»¯Ñ§Ð¾Æ¬ÊÇÒÔ75Ê¿ 1_¦¶25Ê¿ 1_¦¶1Ê¿0. 5mmµÄ²£Æ¬(1)Ϊ¹ÌÏàµ×°å£¬ÔÚÉÏÃæÒ»´Î³ÉÐ͹¹Ôì16¸ö½ðÄÉÃ×·´Ó¦Î¢¿×(5)£¬Ã¿¸ö·´Ó¦Î¢¿×¶¼°üº¬ÓÐÈý¸öµç¼«¹¤×÷µç¼«(3)£¬¸¨Öúµç¼«O)£¬²Î±Èµç¼«¢È£»Ã¿¸ö¹¤×÷µç¼«(3)É϶¼ÐÞÊÎÓй¦ÄÜ»¯µÄÄÉÃײÄÁϺÍÉúÎï·Ö×Ó¸´ºÏ²ã£¬ÔÙÔÚ¸´ºÏ²ãÐÞÊκËÜÕËá»òëĺËËá²¶»ñ̽ÕëÁ´£¬´Ó¶ø½¨Á¢16SrRNAÌØÒìÐÔÐòÁÐʶ±ð²ã¡£ÓÉͼ2¿É¼û£¬Ò»¸ö¿í80mmX40mmX4mmµÄµç»¯Ñ§Ð¾Æ¬¶ÁÊýÆ÷£¬ÓÐÒ»¸öµç»¯Ñ§Ð¾Æ¬¶ÁÊý²Û(6)ºÍÁ½ÅÅ·´Ó¦ÐźÅÊä³öµ¼Ïß(7)¡£ÓÉͼ3¿É¼û£¬½«µç»¯Ñ§Ð¾Æ¬(9)·ÅÈëµ½¶ÁÊýÆ÷(8)оƬ²ÛÀïÃæ½øÐжÁÊý£¬²¢Í¨¹ýÊä³öµ¼Ïß(7)½«·´Ó¦ÐźÅÊä³ö¡£
ȨÀûÒªÇó1.Ò»´ÎÐԵ绯ѧоƬ£¬ÓÐÒ»¸ö²£Á§µ×°å£¬ÆäÌØÕ÷ÔÚÓÚÔÚ²£Á§µ×°åÉÏÓÐ16¸ö·´Ó¦Î¢¿×ºÍµç»¯Ñ§Ð¾Æ¬¶ÁÊýÆ÷Á¬½Ó¡£
2.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄµç»¯Ñ§Ð¾Æ¬£¬ÆäÌØÕ÷ÔÚÓÚÿ¸ö·´Ó¦Î¢¿×¶¼º¬ÓÐÈýµç¼«Ìåϵ ¸¨Öúµç¼«¡¢²Î±Èµç¼«¡¢¹¤×÷µç¼«£»¸¨Öúµç¼«ºÍ²Î±Èµç¼«·Ö±ð»·ÈÆÔÚ¹¤×÷µç¼«ÖÜΧ¡£
3.¸ù¾ÝȨÀûÒªÇó2ËùÊöµÄÈýµç¼«Ìåϵ£¬ÆäÌØÕ÷ÔÚÓÚ¸¨Öúµç¼«¡¢²Î±Èµç¼«¡¢¹¤×÷µç¼«¾ùÓɽðÄÉÃ×µ¼µç²ÄÁϹ¹³É¡£
4.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄµç»¯Ñ§Ð¾Æ¬£¬ÆäÌØÕ÷ÊÇ»¹°üÀ¨¼ì²â̽Õ룬ÐÔÖÊÊÇDNA»òPNA̽Õë¡£
רÀûÕªÒªÐÂÐ͵ڶþ´úÉúÎïоƬһ´ÎÐԵ绯ѧоƬ£¬¿ÉÒÔÓÃÐÂÐÍÄÉÃײÄÁϼ°ÉúÎïѧ·Ö×Ó½øÐÐÐÞÊΣ¬²¢Óë¶àͨµÀºãµçλÒÇÏà½áºÏ¡£ÔÚÿÕŵ绯ѧоƬÉ϶¼º¬ÓÐ16¸ö¶ÀÁ¢·ÖÎö΢¿×£¬µç»¯Ñ§Ð¾Æ¬¼¯³É¶È¸ß£¬Ò×ÓÚÅúÁ¿Éú²ú£¬ÐÔÖÊÎȶ¨£¬·Ç³£ÊʺÏÔÚÒ½Ôº¼ìÑé¿ÆÓ¦Óá£ÀûÓôËоƬ¿ÉÒÔÖ±½Ó¶ÔÁÙ´²Äò·³£¼û²¡Ô¾ú½øÐмø¶¨¼°Ò©Ãô·ÖÎö£¬¶ø²»ÓöԲ¡Ô¾ú½øÐÐÅàÑø»ò»ùÒòÀ©Ôö£¬ÁÙ´²±ê±¾¼ì²âÁ¿Ð¡(3-50¦ÌL)£¬×¼È·¶È¸ß£¬ÌØÒìÐÔÇ¿£¬Õï¶Ïʱ¼ä¶Ì£¬¼ì²â³É±¾µÍ¡£
Îĵµ±àºÅG01N27/27GK202220175SQ20112017543
¹«¿ªÈÕ2012Äê5ÔÂ16ÈÕ ÉêÇëÈÕÆÚ2011Äê5ÔÂ27ÈÕ ÓÅÏÈȨÈÕ2011Äê5ÔÂ27ÈÕ
·¢Ã÷Õ߸ÊÏÈÔÆ, л¹úÃ÷, ÕÔ³¯»Ô ÉêÇëÈË:¸ÊÏÈÔÆ, л¹úÃ÷, ÕÔ³¯»Ô